ArticleCancer medicine2025
Mechanistic Insights Into the Tumor-Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In Vitro Analysis.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOvarian cancer (OC) remains one of the most lethal gynecological malignancies, characterized by late-stage diagnosis and high recurrence rates. Despite advances in treatment, the overall survival rate for OC patients remains low due to the lack of reliable biomarkers for early detection and prognosis. Thus, there is an urgent need for novel diagnostic and prognostic biomarkers to improve patient outcomes. In this study, we explored the potential role of the KCTD (Potassium Channel Tetramerization Domain-containing) family genes in OC.
methodsThis study utilized comprehensive in silico and in vitro experiments.
resultsFirstly, we analyzed the expression patterns of KCTD genes across 12 OC cell lines and 6 normal control cell lines using RT-qPCR, identifying significant upregulation of KCTD5, KCTD9, KCTD12, and KCTD16, while KCTD2, KCTD10, KCTD15, and KCTD21 were downregulated. ROC analysis revealed high diagnostic accuracy for KCTD2, KCTD5, KCTD9, and KCTD12. Further stage-specific analysis indicated that KCTD2, KCTD5, KCTD15, and KCTD21 are associated with OC progression. Functional assays in SKOV3 and A2780 cells demonstrated that overexpression of KCTD2 and KCTD10 significantly inhibited cell proliferation, migration, and colony formation, suggesting their tumor-suppressive roles. Immune and drug sensitivity analyses revealed that KCTD genes may influence immune evasion and chemoresistance in OC. Additionally, miRNA analysis identified potential regulatory mechanisms of KCTD expression.
conclusionCollectively, our findings indicate that KCTD family members serve as promising biomarkers, offering new insights into therapeutic strategies for OC management. Further validation in clinical settings is essential to establish their potential as therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.